Discriminating between protective and enhancing HIV antibodies

AIDS Res Hum Retroviruses. 1990 Feb;6(2):243-9. doi: 10.1089/aid.1990.6.243.

Abstract

Most attempts to produce a vaccine against HIV-1 infection are utilizing envelope protein components. Hypothetically such vaccine candidates could stimulate production of antibodies that enhance HIV-1 infection via the macrophage route of entry and, consequently, cannot be detected in the conventional neutralization assay. To study this hypothesis we report an assay designed to evaluate the protective/enhancing activity of serum from seropositive immunized or infected individuals. Highly purified activated FcR-bearing monocytes-macrophages were infected with HIV-1 in the presence of the sera, then washed and cocultured with activated peripheral blood mononuclear cells (PBMC) from a normal donor. Productive viral infection, as evaluated by p24 antigen semiquantitative assay in the culture supernatants, allow evaluation of protective/enhancing activity of the sera. The data clearly show that protective rather than enhancing activity is present in the serum of env protein-immunized individuals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / immunology*
  • Cells, Cultured
  • Gene Products, gag / immunology*
  • HIV Antibodies / immunology*
  • HIV Antigens / immunology*
  • HIV Core Protein p24
  • HIV Seropositivity / immunology
  • HIV-1 / immunology*
  • Humans
  • Kinetics
  • Leukocytes, Mononuclear / immunology
  • Leukocytes, Mononuclear / microbiology
  • Macrophages / microbiology
  • Monocytes / microbiology
  • Random Allocation
  • Viral Core Proteins / immunology*

Substances

  • Gene Products, gag
  • HIV Antibodies
  • HIV Antigens
  • HIV Core Protein p24
  • Viral Core Proteins